CR20150272A - Derivado de hidantoina - Google Patents

Derivado de hidantoina

Info

Publication number
CR20150272A
CR20150272A CR20150272A CR20150272A CR20150272A CR 20150272 A CR20150272 A CR 20150272A CR 20150272 A CR20150272 A CR 20150272A CR 20150272 A CR20150272 A CR 20150272A CR 20150272 A CR20150272 A CR 20150272A
Authority
CR
Costa Rica
Prior art keywords
hydantoin derivative
hydantoin
derivative
formula
acceptable salts
Prior art date
Application number
CR20150272A
Other languages
English (en)
Inventor
Yoshikazu Nishimura
Toru Esaki
Tatsuya Tamura
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CR20150272A publication Critical patent/CR20150272A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

La presente invención proporciona compuestos representados por la fórmula (I) que se muestra a continuación y sus sales farmacológicamente aceptables: en donde R1, R2, R3, y R4 son como se definen en las reivindicaciones.
CR20150272A 2012-12-10 2015-05-21 Derivado de hidantoina CR20150272A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012269178 2012-12-10
PCT/JP2013/083022 WO2014092061A1 (ja) 2012-12-10 2013-12-10 ヒダントイン誘導体

Publications (1)

Publication Number Publication Date
CR20150272A true CR20150272A (es) 2015-07-09

Family

ID=50934349

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150272A CR20150272A (es) 2012-12-10 2015-05-21 Derivado de hidantoina

Country Status (34)

Country Link
US (5) US9428505B2 (es)
EP (1) EP2930176B1 (es)
JP (1) JP5951799B2 (es)
KR (1) KR102168738B1 (es)
CN (1) CN104854106B (es)
AU (1) AU2013358167B2 (es)
BR (1) BR112015012411B1 (es)
CA (1) CA2892621C (es)
CL (2) CL2015001391A1 (es)
CR (1) CR20150272A (es)
DK (1) DK2930176T3 (es)
ES (1) ES2663797T3 (es)
HR (1) HRP20180647T1 (es)
HU (1) HUE037530T2 (es)
IL (1) IL238277B (es)
LT (1) LT2930176T (es)
MA (1) MA38250B1 (es)
MX (1) MX2015007309A (es)
MY (1) MY178583A (es)
NO (1) NO2930176T3 (es)
NZ (1) NZ707946A (es)
PE (1) PE20151295A1 (es)
PH (1) PH12015501146B1 (es)
PL (1) PL2930176T3 (es)
PT (1) PT2930176T (es)
RS (1) RS57190B1 (es)
RU (1) RU2678984C2 (es)
SA (1) SA515360528B1 (es)
SG (1) SG11201504204XA (es)
SI (1) SI2930176T1 (es)
TW (1) TWI615394B (es)
UA (1) UA115072C2 (es)
WO (1) WO2014092061A1 (es)
ZA (1) ZA201503597B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2433940B9 (en) 2009-04-28 2015-10-28 Chugai Seiyaku Kabushiki Kaisha Spiroimidazolone derivative
DK2930176T3 (en) * 2012-12-10 2018-03-19 Chugai Pharmaceutical Co Ltd hydantoin derivatives
EP3153166B1 (en) * 2014-06-09 2022-08-03 Chugai Seiyaku Kabushiki Kaisha Hydantoin derivative-containing pharmaceutical composition
TW202019416A (zh) 2018-07-30 2020-06-01 日商中外製藥股份有限公司 乙內醯脲衍生物的固體分散體
CN110464002A (zh) * 2019-09-12 2019-11-19 西南石油大学 一种天然冰粉的制备方法及其应用
JPWO2024143501A1 (es) 2022-12-28 2024-07-04

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1135470A (ja) * 1997-07-23 1999-02-09 Teijin Ltd ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤
JP3913983B2 (ja) 1998-12-11 2007-05-09 エフ．ホフマン−ラ ロシュ アーゲー ＴＮＦ−α阻害剤としての環式ヒドラジン誘導体
CA2420759A1 (en) 2000-08-30 2003-02-27 Daishiro Miura Parathyroid hormone production inhibitors containing vitamin d3 derivatives
CA2425283A1 (en) * 2000-10-26 2002-05-02 Pfizer Products Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
AR038658A1 (es) * 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
WO2003105099A1 (en) * 2002-06-06 2003-12-18 Donnelly Corporation Interior rearview mirror system with compass
WO2005077959A1 (en) 2004-02-11 2005-08-25 Smithkline Beecham Corporation Pth agonists
US20070123548A1 (en) * 2004-02-11 2007-05-31 Cowan David J Pth agonists
WO2006041830A2 (en) 2004-10-07 2006-04-20 Merck & Co., Inc. Cgrp receptor antagonists
WO2007135417A1 (en) 2006-05-19 2007-11-29 James Black Foundation Benzotriazepinone derivatives
EP2035420A2 (en) 2006-06-20 2009-03-18 Wyeth a Corporation of the State of Delaware Kv1.5 potassium channel inhibitors
CA2689560A1 (en) 2007-06-07 2008-12-11 F.Hoffmann-La Roche Ag Prolinamide derivatives as nk3 antagonists
EA017919B1 (ru) 2007-12-10 2013-04-30 Новартис Аг Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
WO2010045229A2 (en) 2008-10-13 2010-04-22 University Of Rochester Protecting and repairing cartilage and musculoskeletal soft tissues
EP2433940B9 (en) * 2009-04-28 2015-10-28 Chugai Seiyaku Kabushiki Kaisha Spiroimidazolone derivative
DK2930176T3 (en) * 2012-12-10 2018-03-19 Chugai Pharmaceutical Co Ltd hydantoin derivatives
EP3153166B1 (en) * 2014-06-09 2022-08-03 Chugai Seiyaku Kabushiki Kaisha Hydantoin derivative-containing pharmaceutical composition

Also Published As

Publication number Publication date
SI2930176T1 (en) 2018-06-29
CL2017000069A1 (es) 2017-08-25
RU2678984C2 (ru) 2019-02-05
SA515360528B1 (ar) 2018-05-24
TW201439092A (zh) 2014-10-16
MA38250B1 (fr) 2017-10-31
HRP20180647T1 (hr) 2018-06-01
RS57190B1 (sr) 2018-07-31
US9428505B2 (en) 2016-08-30
CN104854106A (zh) 2015-08-19
KR20150092275A (ko) 2015-08-12
PE20151295A1 (es) 2015-10-10
BR112015012411B1 (pt) 2021-10-05
PH12015501146A1 (en) 2015-08-10
HUE037530T2 (hu) 2018-09-28
AU2013358167A1 (en) 2015-04-09
RU2015127624A (ru) 2017-01-16
NO2930176T3 (es) 2018-07-07
MY178583A (en) 2020-10-16
IL238277B (en) 2018-01-31
DK2930176T3 (en) 2018-03-19
WO2014092061A1 (ja) 2014-06-19
MX2015007309A (es) 2015-09-10
NZ707946A (en) 2019-11-29
CL2015001391A1 (es) 2015-07-31
TWI615394B (zh) 2018-02-21
SG11201504204XA (en) 2015-07-30
EP2930176A1 (en) 2015-10-14
AU2013358167B2 (en) 2017-09-14
UA115072C2 (uk) 2017-09-11
JPWO2014092061A1 (ja) 2017-01-12
JP5951799B2 (ja) 2016-07-13
US20160326175A1 (en) 2016-11-10
PT2930176T (pt) 2018-04-03
IL238277A0 (en) 2015-06-30
KR102168738B1 (ko) 2020-10-22
CN104854106B (zh) 2017-07-04
PH12015501146B1 (en) 2017-10-27
CA2892621A1 (en) 2014-06-19
EP2930176A4 (en) 2016-06-01
US20150274727A1 (en) 2015-10-01
PL2930176T3 (pl) 2018-07-31
HK1209735A1 (en) 2016-04-08
MA38250A1 (fr) 2017-02-28
US20220162208A1 (en) 2022-05-26
CA2892621C (en) 2021-02-16
US20210024524A1 (en) 2021-01-28
LT2930176T (lt) 2018-04-10
ES2663797T3 (es) 2018-04-17
ZA201503597B (en) 2016-09-28
BR112015012411A2 (pt) 2017-07-11
US20180237436A1 (en) 2018-08-23
EP2930176B1 (en) 2018-02-07

Similar Documents

Publication Publication Date Title
UY34318A (es) ?derivados de isotiazolina útiles como compuestos insecticidas?
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
UY34523A (es) Derivados de betulina
UY33936A (es) Derivados de fluoro-piridinona útiles como agentesantibacterianos.
UY34472A (es) Derivados modificados de 4-fenil-piridina
GT201400290A (es) Carboxamidas heterociclicas fungicidas
CR20140547A (es) Compuestos que contienen pirazol sustituido y su uso como plaguicidas
UY34075A (es) ?compuestos insecticidas a base de derivados de ariltioacetamida
ES2530968T3 (es) Pirrolobenzodiazepinas y conjugados de las mismas
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY34591A (es) Compuestos de imidazopirrolidinona
UA113643C2 (xx) N-цикліламіди як нематоциди
UY34117A (es) Derivados de polimixina útiles como agentes antibacterianos
UY34336A (es) Derivados 5-fluoro pirimidina disustituidos que contienen un grupo sulfoximina
UY34778A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA HETEROCÍCLICOS SUSTITUÍDOS?.
UY34302A (es) COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2- AMINA
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
UY34818A (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
UY34034A (es) Triazolopiridinas
UY34013A (es) ?compuestos de cromenona con actividad anti-tumoral?.
CR20130625A (es) Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
CY1117163T1 (el) Ιμιδαζοπυριδαζινες ως αναστολεις κινασης ακτ
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas